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Abstract
Trypanosoma cruzi (T. cruzi) is the causative agent of Chagas disease (ChD), an
emerging illness prevalent in South and Central America. Presently, benznidazole and
nifurtimox are the only two clinically available drugs against T. cruzi, which have high
toxicity and limited efficacy in the chronic phase of the disease. This ailment affects 810 million people and has become an emerging concern in the U.S leading to an urgent
need for the discovery of new treatments. Despite all efforts, there is no human vaccine
available. Therapeutic vaccines are a possible option for chronic ChD in which the
vaccine is used after infection, by inducing anti-trypanocidal immunity. MASPpep is a
synthetic 20-mer peptide (DAENPGGEVFNDNKKGLSRV) which is a derivative of T.
cruzi mucin associated surface protein (MASP) that has been previously investigated as
a prophylactic vaccine. This study demonstrated that MASPpep conjugated to keyhole
limpet hemocyanin (MASPpep-KLH) elicited a protective Th1 and Th17 immune
response and lytic antibody production against T. cruzi challenged mice. For this
reason, using a therapeutic vaccine in combination with benznidazole is an approach
that is currently under investigation. Here, we investigate immunochemotherapeutic
strategies utilizing peptide vaccine to alter the immune response by combining
conserved MASPpep-KLH antigen in combination with benznidazole to achieve
complete parasitic clearance. Considering the limited efficacy of benznidazole in the
chronic phase of ChD, another approach is to validate N-myristoyltransferase inhibitors
as chemotherapeutic agents. N-myristoyltransferase (NMT) is an enzyme that catalyzes
the transfer of myristoyl-CoA into proteins. Myristoylated proteins are involved in
regulating various cellular functions in eukaryotes. This pervasive modification has
vi

shown to be crucial for protein localization and function of protozoan parasites such as
T. cruzi, and Trypanosoma brucei (T. brucei). Over one hundred myristoylated proteins
have been identified in T. cruzi, predicting that inhibition of NMT will have pleiotropic
effects. Additionally, NMT is expressed in all stages of the parasite. Thus, encouraging
NMT inhibitors as valid drug candidates for the treatment of T. cruzi, which have been
previously evaluated against T. brucei NMT. Respectively, selective NMT inhibitors
DDD1 and DDD5 presented high trypanocidal activity with an EC50 of 0.18 µM and 0.26
µM in intracellular forms of T. cruzi with minimal cytotoxicity. Consequently, antitrypanocidal activity of NMT inhibitors DDD86481 (DDD1) and DDD100097 (DDD5)
were screened in an in vivo murine model for chronic ChD. Compounds DDD1 and
DDD5 significantly reduced parasite load in the murine chronic model without
permissible toxicity. Fundamentally, this immunochemotherapeutic approach is to attain
clearance and protection via treatment with NMT inhibitors while producing a humoral
and cellular immune response by MASPpep-KLH in a mouse model of chronic T. cruzi
infection.
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Chapter 1: General introduction
1.1 Trypanosoma cruzi and Chagas Disease
Trypanosoma cruzi (T. cruzi) is the causative agent of American trypanosomiasis
commonly known as Chagas disease (ChD), which primarily affects people residing in
rural Latin America. In recent years, ChD has become an emerging public health
concern in the U.S., affecting approximately 300,000 people and 18-20 million people
worldwide [1-3]. Other non-endemic countries such as Spain have seen an increase of
infections as a result to migration patterns from asymptomatic infected individuals from
prevalent areas (Figure 1) [4]. ChD primarily affects individuals who live in inadequate
dwellings or rural areas; a few cases occurring in new urban areas due to blood and
congenial transmission.
T. cruzi is a unicellular flagellated protozoan that resides in the feces of infected
triatomine insect vector, popularly known as the “kissing bug”. The primary route of
infection is from a triatomine insect to humans or other mammals depositing its feces on
the host while feeding simultaneously. The metacyclic trypomastigote form of T. cruzi
found in the feces of the triatomine can be mechanically inoculated through the bite
wound or mucous membranes [5]. This enables the parasite to invade host cells,
develop into the intracellular amastigotes form, replicate by binary fission, and transform
again into trypomastigotes [5]. Host cells then rupture releasing the trypomastigotes into
the circulatory system where they can infect neighboring cells and tissues or ingested
by another triatomine in a blood meal. Once ingested, trypomastigotes develop into
epimastigotes in the midgut of the insect vector. These epimastigotes are the noninfective form, which migrate to the hindgut and differentiate into highly infective
1

metacyclic trypomastigotes (Figure 1) [5, 6]. Although, T. cruzi is mainly transmitted
through the feces of an infected kissing bug, other routes of transmission include
congenital (mother to embryo), organ transplantation, blood transfusion, and food
contamination.
ChD is classified in three stages: acute, indeterminate, and chronic phase. The
acute phase is the initial stage of ChD in which parasites persist in the bloodstream at
detectable levels for two to three months after infection [1]. In the acute phase,
individuals are asymptomatic or exhibit mild flu-like symptoms such as fever and
fatigue. Also, in some cases inflammation at the site of inoculation may be presented,
known as chagoma. Development of myocarditis, and meningoencephalitis in acute
infections lead to 5 to 10% fatality rate [7]. In the indeterminate form of ChD,
approximately 70% of individuals are asymptomatic and parasite load becomes
undetectable [7]. Nearly 30 to 40% of individuals progress to the chronic phase and
remain asymptomatic, and continue to serve as a reservoir for T. cruzi [7, 8]. Infected
people develop cardiomyopathy, megacolon, and megaesophagus in chronic ChD,
between 10 and 30 years after initial infection of T. cruzi.
The nitroheterocyclic compounds benznidazole and nifurtimox are the only drugs
currently available for the treatment of ChD. These nitroheterocyclic derivatives are
effective in the acute stage of the disease, but have limited efficacy in the chronic stage
[1]. Moreover, these compounds cause severe side effects, and parasite resistance
strains have emerged. They can only be acquired through the CDC for investigative
purposes, and only Benznidazole has been recently FDA approved for children.
Additionally, long therapeutic regimen consisting of a 60-90 day treatment [2],
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represents a financial burden for underprivileged populations that lack access to
healthcare and transportation. In this regard, the outcome in parasitic resistance is
provoked by incomplete therapeutic schedules. Overall, there is a vital need for
innovative, low toxic and more efficient drugs for the treatment of ChD.
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Figure 1. Documented individuals infected with T. cruzi living in non-endemic countries
[4].
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Figure 2. Life cycle of Trypanosoma cruzi.
Metacyclic trypomastigotes are released through the feces of a triatomine insect and
enter the bite site (1). Inside the host, metacyclic trypomastigotes rapidly invade wound
site, tissues, and mucosa. Trypomastigotes differentiate into intracellular amastigotes
inside the cell (2). Amastigotes continue to replicate and differentiate back into
trypomastigotes (3). The trypomastigotes replicate and rupture the cell, they are then
released into the bloodstream. Once in the bloodstream, trypomastigotes may infect
neighboring cells and tissues or can be ingested by a triatomine insect (4-5).
Trypomastigotes transform into epimastigotes and replicate in the midgut of the insect
vector (6-7). The epimastigotes travel to the hindgut of the triatomine and differentiate
back into highly infective metacyclic trypomastigotes (8) [9].
5

1.2 Therapeutic strategies to treat chronic T. cruzi infection
Benznidazole (BZ) is a nitroimidazole derivative exhibiting higher anti-parasitic
activity than the other optional treatment (Nifurtimox). The FDA has recently approved
this nitroimidazole derivative for children 2-12 years old as of 2017. It is distributed by
Argentine chem group, Exceltis. The standard dosages are 10 mg/kg/day for children
younger than 12 years, administered orally twice a day for 60 days. In addition to the
extensive treatment regimen, BZ continues to have limited efficacy in the chronic phase
of ChD. Discontinuation of treatment is often due to severe side effects such as nausea,
anemia, dermatitis, and neuropathy.
BZ inhibits the DNA, protein, and lipid synthesis in T. cruzi, accelerating parasitic
clearance by inducing phagocytosis and altering pro/anti-inflammatory cytokines to
minimize IL-10, IL-1β and IL-6 synthesis [10]. In result of high levels of proinflammatory
cytokines (IFN-γ) induced, BZ is most successful during the acute phase of the disease
with 65 to 86% cure rate [3, 11]. Studies have shown mice deficient in IFN-γ, IL-12 and
TNF-α have an increased parasitic burden with BZ treatment [3, 11].
It has been speculated that the standard dosage (100mg/kg/mouse) for a murine
model may be insufficient for parasitic clearance in the chronic phase, due to its
manifestations in tissues where the replicative form of T. cruzi resides [3]. BZ is able to
distribute to multiple organs, however there has been evidence of limited absorption
after the first-pass metabolism in the liver [3]. In this regard, there is a need to
improve the efficacy of this frontline drug for ChD.

6

Chapter 2: Validation of N-myristoyltransferase inhibitors as
treatment for the early and late acute phase of ChD
2.1

N-myristoyltransferase
Myristoylation is a co- and post-translational modification which corresponds to

the attachment of a 14-carbon fatty acid, myristate, from myristoyl coenzyme A (CoA) to
the amino terminal of the glycine residue [12, 13]. The catalysis occurs subsequently of
initiator methionine removal. Myristoyl-CoA:protein N-myristoyltransferase (NMT)
catalyzes the linkage of myristic acid to the N-terminal glycine in eukaryotic proteins [1214]. The forming NMT complex undergoes a Bi-Bi reaction mechanism where NMT first
binds to myristoyl-CoA to induce a conformational change that will allow the peptide to
bind after. The myrsitoyl-CoA:NMT-peptide is then catalyzed, resulting in the release of
the CoA product (Figure 2.) [14]. Modification occurs and mediates stable protein
interactions that are essential for localization and signal transduction. During protein
synthesis, a co-translation modification occurs in the ribosome, which then mediates
protein-protein interactions. After a co-translation modification reaction occurs during
protein synthesis in the ribosome which then regulates the stability of protein-protein
interactions by increasing hydrophobicity and inducing a conformational alteration to
stabilize membrane bound proteins [12, 15]. When post-translation modification reacting
occurs, it is due to apoptosis where proteolysis by caspases reveal hidden Nmyristoylation structure [5]. These interfaces are essential for localization, regulation
and signal transduction of proteins. It has been validated that NMT is crucial for the
survival

of

Saccharomyces

cerevisiae,

Candida

albicans,

and

Cryptococcus

neoformans [16]. Human and fungal NMT have demonstrated high homology of
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myritoyl-CoA binding sites by bioinformatic approaches [17]. Conversely, peptide
binding specificities vary amongst each species, which make these sites eligible antifungal chemotherapeutic targets. Also, NMT is well conserved in Trypanosoma brucei
(T. brucei), Leishmania major (L. major), Leishmania donovani (L. donovani), and
Plasmodium falciparium (P. falciparum) [18-20]. Yet, only a few T. cruzi N-myristoylated
proteins have been identified, which includes phosphoinositide-specific phospholipase
C (PLC) and the flagellar calcium-binding protein (FCaBP), which are present in all
stages of the parasite [14, 21]. Over 100 proteins have been classified to be Nmyristoylated

and

is

the

prerequisite

of

post-translational

modification

prior

myristoylation in many proteins, called palmitoylation [22]. Palmitoylation is the covalent
attachment of palmitic acid (C16:0) to cysteine residues and has been validated to be a
necessity for flagellar membrane sorting in kinetoplastids [23]. The FCaBP found in T.
cruzi is a myristoyl/palmitoyl-acylated protein that is cytoplasmic [13]. Trypanosomatids
have a surface protein coat that is composed of variant surface glycoproteins (VSG),
that consists of fatty acid myristates in the glycophosphatidylinositol (GPI) anchor, which
they synthesize these fatty acids from the ER. Moreover, trypanosomes fuse myristate
acid into the GPI-anchors to transfer surface molecules such as glycoproteins outside
the plasma membrane [14]. Majority of NMT enzymatic activity is cytosolic, additionally,
previous studies have demonstrated endoplasmic reticulum (ER) activity (Figure 4.) [15,
21]. These facts manifest the importance of NMT in T. cruzi.
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Figure 3. N-myristoylation reaction mechanism.
Myristoyl-CoA binds first to the enzyme to form the NMT: myristoyl-CoA complex,
inducing a conformational change that allows binding of the peptide. Nucleophilic
substitution proceeds via attack by the N-terminal glycine amine in the peptide on the
myristoyl-CoA thioester. CoA is released first, followed by the myristoyl peptide [12].
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Figure 4. TcNMT is expressed in all T. cruzi stages and is associated to the
endoplasmic reticulum (ER) [21]. Colocalization with BiP suggests that NMT is partial
associated to the ER of T. cruzi.
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2.2 Pyrazole sulphonamide compounds and preliminary data
NMT characterization and function has not been extensively investigated in T.
cruzi, although preliminary data suggests NMT inhibitors are potential chemotherapeutic
drugs (Figure 5). A 63,362 diverse compound library was screened for anti-TbNMT
activity, which recognized numerous hits on the pyrazole sulphonamide scaffold [16].
These pyrazole sulphonamide compounds are known as NMT inhibitors, that have
resulted in complete clearance of human T. brucei with IC50 values as low as 0.002 µM
[24]. In this regard, a series of inhibitors were selected by high-throughput screening
and validation of these anti-trypanocidal inhibitors. NMT inhibitors DDD86481 (DDD1)
and DDD100097 (DDD5) showed IC50 values of 0.18 µM and 0.26 µM respectively
against T. cruzi intracellular amastigotes (Table 1) [21]. Moreover, the minimum amount
of T. cruzi infected host cells with at least five parasites or more were detected at a low
concentration of 10 µM (Figure 5) [21]. Therefore, DDD1 and DDD5 displayed utmost
potential to investigate an in vivo murine model for the treatment of ChD in the
acute phase.
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Table 1. EC50 values for DDD86481 (DDD1) and DDD100097 (DDD5)
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A

B

Figure 5. Percentage of human osteoblasts infected with at least 5 or more parasites.
(A) Treatment of human osteoblasts with DDD1. (B) Treatment of human osteoblasts
with DDD5.
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2.3 Hypothesis

Myristoylation is a modification that has the ability to change the physiology of T.
cruzi. NMT inhibitors have been previously validated to prevent the involvement of Nmyristoyltransferase in the biosynthesis of other viable enzymes allowing to reduce
parasite burden at submicromolar concentrations. For this reason, we hypothesized
that the NMT inhibitors (DDD1 and DDD5) will strongly inhibit and maximize
efficacy to clear T. cruzi infection in an in vivo model for early and late acute
phase of Chagas disease.

2.4 Specific Aims

Aim 1: To evaluate the effects of two selective NMT inhibitors (DDD1 and DDD5) in a
murine model of the early and late acute phase of ChD.

Aim 2: Purification of recombinant protein TcNMT for the pharmacokinetic and
enzymatic in vitro study.
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2.5

Materials and Methods

2.5.1 Compounds
Compounds DDD86481 (DDD1) and DDD100097 (DDD5) were synthetized and
obtained from Dr. Stephen Brand and Dr. Paul Wyatt (University of Dundee, UK). Patent
WO2010/026365 [25].

2.5.2 T. cruzi culture
T. cruzi CL-Brener-expressing Luciferase (LUC) and Y strain trypomastigotes were
cultured by passage through BALB/c mice and monkey kidney epithelial cells (LLCMK2). After 5 passages, BALB/c mice were infected with 104 trypomastigotes.
Bloodstream trypomastigotes were collected 4 days post-infection and used to infect
LLC-MK2 cells. Infected cells were incubated for 6 to 12 days at 37˚C supplemented
with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% heat
inactivated fetal bovine serum (iFBS) and 1% penicillin-streptomycin. Tissue culture
cell-derived trypomastigotes of T. cruzi CL-Brener-LUC were collected 9 -12 days after
infection of LLC-MK2.

2.5.3 Mice strains
Female BALB/c mice (6-8 week old) were breed at UTEP’s animal facility. The in vivo
trypanosomiasis experiments were performed minimizing the distress and pain for the
animals following the NIH guidance and animal protocol (A-2125) approved by UTEP’s
Institutional Animal Care and Use Committee (IACUC).
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2.5.4 In vivo experiments for the acute and chronic phase of ChD
BALB/c female mice were separated into 5 groups of 5 mice (n=5). For the acute phase,
the first control group was treated with 100 µl of phosphate buffer saline (PBS, drug
diluent) twice a day. The second control group (reference group) was treated with BZ;
50 mg/kg twice a day. The two experimental groups were treated with DDD1 (20 mg/kg)
and DDD5 (50 mg/kg) twice a day. In the late acute phase, one dose was administered
for each compound: bz (50 mg/kg), DDD1 (20 mg/kg), and DDD5 (50 mg/kg). T. cruzi
blood stream trypomastigotes were obtained as described previously. Suspension of
103 and 104 parasites per milliliter of DMEM were inoculated via intraperitoneal (i.p.)
injection to designated mice. Inhibitors were administered 3 days post-infection (early
acute phase) and 14 days post-infection (late acute phase) via oral gavage, twice and
once a day for 5 to 12 days.

2.5.5 Parasite quantification in the acute phase of ChD
To verify the number of parasites circulating the bloodstream in the acute phase, 5 µl of
blood were withdrawn from the tail vein from each mouse, from 3 days post-infection
(dpi) to 15 dpi and quantified under a light microscope. Parasite quantification was
obtained by the Brener method as previously described [26] .

2.5.6 Bioluminescence Imaging
BALB/c female mice were injected i.p. with 150 mg/kg of potassium salt D-luciferin
(GoldBio Biotechnology), followed by 2.5 % isoflurane exposure. Ten minutes after Dluciferin administration, mice were placed and images were acquired using the IVIS
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Lumina III In Vivo Imaging System (PerkinElmer). Auto exposure times varied between
1 and 90 seconds depending on signal intensity [27]. After imaging, mice were
recovered and placed in cages below a heating pad. To assess parasite burden,
regions of interest (ROIs) were drawn using Livingimage v.4.3 software to quantify
bioluminescence expressed as total flux (photons/second (p/s)) as previously described
[27].

2.5.7 Expression and Purification of TcNMT
TcNMT gene was amplified from T. cruzi Y-strain genomic DNA using the NMT forward
primer (5’-GGATCCATGGCAGAAGAGGGTTCAGGT-3’) and reverse primer (5’GAATTCCTA- TAGCATGAACAATCCCACGTC-3’). The BamHI and EcoRI sites of
vector pRSET-A (Life Technologies) were selected to clone the amplified fragment. The
plasmid incorporated with TcNMT was transformed in Escherichia coli BL21 (DE3).
Expression of N-terminal His6-tagged recombinant TcNMT was induced after growth at
37˚C to an A600 (absorbance) of 0.6 by addition of isopropyl ß-D-thiogalactoside (IPTG)
to a 1 mM final concentration. Expression was verified by SDS-PAGE from different
time points after induction (0, 0.5, 1, 2, 3, 4, and 18 hrs). After further growth at 18˚C
overnight, bacterial cells were lysed in ice-cold buffer A (50mM Tris/HCL, pH 8, and 300
mM NaCl) and centrifuged at 18,000 xg for 45 min to pellet insoluble material. The His6tagged protein was fractioned with imidazole (75mM imidazole in buffer A) and dialyzed
extensively to 50 mM Tris/HCl (pH 8).
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2.6 Results
2.6.1 Evaluation of NMT inhibitors in the acute phase
DDD1 and DDD5 were evaluated as anti-trypanocidal agents in an in vivo murine
model for the acute phase of ChD. Quantification of parasitemia and treatment was
initialized three days post-infection for a total of 12 consecutive days. The oral dose of
NMT inhibitors administrated was 10 mg/kg and 50 mg/kg twice a day for 5 to 12 days
respectively. BZ was given for 5 days at 50 mg/kg twice a day. We were able to observe
that mice treated with the vehicle control group (PBS) developed a high parasitemia
peak at seven days post infection, indicating excess number of parasites in the blood. In
contrast, groups treated with the reference drug BZ and experimental groups (DDD1
and DDD5) develop low parasitemia throughout the infection, indicating high efficacy of
DDD1 and DDD5. Therefore, DDD1 and DDD5 are potential chemotherapeutic
treatments against T. cruzi infection in the acute phase of the disease.

18

Figure 6. Determining anti-parasitic activity of NMT inhibitors (DDD1 and DDD5) in the
murine model of early acute T. cruzi infection by quantification of trypomastigotes/mL 3
dpi. BZ (red) and DDD5 (green) treatment was administered from 3 to 7 dpi, while
DDD1 (purple) was administered from 3 to 12 dpi.
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2.6.2 Bioluminescent in vivo imaging for quantification of parasite burden in the
late acute model of ChD
BALB/c mice infected i.p. with 103 CL Brener-LUC trypomastigotes were
observed by in vivo bioluminescent imaging. In this experimental late acute model,
parasitemia peaked after 14 dpi and an observable reduction in parasite load as it
progressed from late acute into the chronic phase 48 dpi, respectively. After 14 dpi, the
mice were treated daily for 5 days by oral gavage with BZ (50 mg/kg). The experimental
groups were treated daily with DDD1 for 7 days (50 mg/kg) and DDD5 for 5 days (100
mg/kg) via oral gavage. As observed in Figure 7A and 7B, the parasite load diminished
after 7 days of single dose treatments of DDD1 and remained at low observable
parasite levels. Respectively, a second peak was observed in the vehicle group and
DDD5 group, which is the result of free parasites. This could be the outcome of low
efficacy in DDD5, which may indicate a second daily dose is required for this inhibitor.
Moreover, treatment with NMT inhibitors DDD1 and DDD5 were able to reduce parasite
burden observed by bioluminescence in comparison with vehicle control group (Figure
7B). Mice in each group fluctuated in weight at the beginning due to the T. cruzi
infection. However, no significant weight lost was observed with both DDD1 and DDD5
treatments (Figure 7C). Therefore, inhibitor DDD1 shows to be a promising therapeutic
compound against T. cruzi infection in a mouse model. Moreover, the efficacy of DDD5
could be improved by including a second dose parallel to the acute treatment (Figure 6).
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C

Figure 7. Quantification of ventral bioluminescence after treatment with NMT inhibitors
and weight observation after initial treatment. (A) Treatment started at 14 dpi for a total
of 10 days by oral gavage. Parasite bioluminescent intensity decreased considerably
after 7 days of treatment with DDD1 (green), in comparison to BZ (blue). DDD5 (purple)
withheld a lower parasite burden compared to the vehicle control group (PBS) (red). (B)
Images of ventral view of BALB/c mouse were acquired in chronological order from 14
to 90 dpi. Treatment was initiated the day following the parasitemia peak of the acute
phase. The log10 scale shows bioluminescence intensity from a minimum of 1.7x104
(blue) to high 9.4x107 (red). (I) Infected, vehicle control. (II) Infected, treated with BZ at
50 mg/kg from 14 to 18 dpi. (III) Infected, treated with DDD1 at 20 mg/kg from 14 to 18
dpi. (IV) Infected, treated with DDD5 at 50 mg/kg from 14 to 22 dpi. (C) Normalized
mice weight, groups treated with vehicle control (PBS), BZ, and NMT inhibitors DDD1
and DDD5.
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2.6.3 Expression and purification of recombinant TcNMT
The TcNMT gene was cloned into pRSET-A containing His6- tagged enzyme
(Life Technologies) for expression. TcNMT was found in the insoluble fraction of E. coli
when expressed at 37°C and 30°C in the small protein expression (Figure 9). TcNMT
was expressed at 30˚C, samples were obtained from 0, 0.5, 1, 2, 3, 4, and 18 hrs postinduction. Each sample was then analyzed by SDS-PAGE, indicating the protein
consists of soluble and insoluble properties. However, expression has been previously
optimized to obtain a soluble protein. For future directions, TcNMT will be expressed at
18°C, and purified by metal ion affinity chromatography using a HisTrap HP column (GE
Healthcare Life Sciences). Once the activity of the recombinant protein is interpreted, it
may be utilized for TcNMT biochemical characterization.
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Figure 8. Small expression of TcNMT in E. coli. Soluble (S) and insoluble (P) 1 mL
fractions were obtained from the sample at different time points and analyzed by SDSPAGE.
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2.7 Discussion and future work

ChD is a neglected tropical disease that has become a major public health
concern in Latin America and is increasingly prevalent in other regions as a result of
migration, affecting one third of the global population [28]. This ailment is dependent on
limited sources that are outdated, highly toxic and have poor efficacy in the chronic
phase. In the long term infection of the chronic mouse model of T. cruzi has a
disadvantage when investigating the development of the disease, due to intracellular
amastigotes residing in smooth tissue, in contrast to the acute phase where circulating
trypomastigotes can be readily detected [27]. T. cruzi primarily dwells in the
gastrointestinal tract during the chronic infection, and mice have also shown to develop
chronic myocarditis and cardiac fibrosis [27].
Parasites are able to obtain fatty acids from either the host or synthesize their
own. In T. brucei, once supplied with lipid depleted medium, fatty acid synthesis is
mediated, validating that presence of fatty acids in the environment is crucial for the
survival of protozoans [29]. Abundant proteins such as the GPI-anchor and VSG require
myristoylation to tether molecules out of the membrane. The addition of this fatty acid to
proteins found in trypanosomatids, such as T. brucei, T. cruzi, and L. major is critical for
the survival, replication and virulence of these parasites [13]. After the addition of the
myrsitate acid, N-myristoltransferase catalyzes the fatty acid and allows conformational
change for stronger protein interactions which are required for trypanosmatid structures
including the kinetoplast, flagellum, and flagellar pocket [13]. Flagellar calcium binding
protein (FcaBP) and phosphatidylinositol-phospholipase C are N-myristoylated proteins
in T. cruzi required for expression and localization of the parasite [21]. Furthermore,
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NMT inhibitors are anti-fungal drugs that also exhibit anti-trypanosomidal activity,
triggering pleiotropic effects in T. brucei and T. cruzi. NMT inhibitors DDD86481 (DDD1)
and DDD100097 (DDD5) strongly inhibit the proliferation of amastigotes with no evident
signs of cytotoxic effects at concentrations as low as 1.7 µM and 2.6 µM respectively.
For this reason, T. cruzi N-myristoyltransferase has been validated as a potential
chemotherapeutic target.
DDD1 and DDD5 were able to display strong efficacy and rapid reduction of
parasitic burden in early and late acute stages of T. cruzi (Figure 6 and 7A). On the
other hand, in the chronic infection, DDD5 treated mice developed parasitemia following
treatment, which indicates the compound is not as efficient and potent as DDD1, and a
second daily dose could be necessary. The anti-parasitic activity in the in vivo murine
model for acute ChD will be further assessed. Furthermore, pharmacokinetics and
distribution properties of NMT inhibitors will also be evaluated.
For future work, the in vivo experiments will be repeated at single doses for both
acute and chronic phase of T. cruzi. In the chronic phase, parasites are localized in
smooth tissues including the gastrointestinal tract, however can also be detected in
heart tissues. In the acute phase, parasites are circulating the bloodstream and reside
in the spleen and heart. For this reason, blood and organs such as the heart, liver,
spleen, and gastrointestinal tract were collected after 90 dpi to quantify parasite load via
quantitative real time PCR. Additionally, organs and selective tissues from all mice will
be assessed for infection by ex vivo imaging at initial, completion of treatment, and at
the final experimental endpoint. In this assay, the animal will be perfused with 150
mg/kg of D-luciferin in PBS then selected organs and tissues will be collected and
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imaged under the IVIS Lumina III In Vivo Imaging System as previously described [27].
To further assess if the NMT inhibitors were able to clear T. cruzi infection in the chronic
phase of ChD, the oral dose was reduced from two doses to one dose of 20 mg/kg for
12 days in the murine model. In this experimental model, the goal is to reduce the
length and dosage of treatment for acute and chronic T. cruzi infections.
In the case of the chronic infection, parasites reside within host cells, therefore
maximal absorption of anti-T. cruzi drugs must be lipophilic to be able to enter cell
membranes and smooth tissues [30]. The structural differences between DDD1 and
DDD5 inhibitors may affect binding and drug potency. To determine distribution of the
compounds in the plasma, compounds will be administered with a single dose. DDD1
will be given through the oral route at 20 mg/kg, DDD5 at 50 mg/kg and BZ at 50 mg/kg
and drug plasma concentration will be analyzed by liquid chromatography mass
spectrometry (LC-MS).
Moreover, enzymatic activity of inhibitors will be measured by UV-vis binding
assay though a UV-spectrophotometer. This technique will help establish binding affinity
hits of NMT inhibitors at different concentrations; absorbance values determine the
ligand and enzyme concentration used to reach saturation [31, 32].
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Research Strategy

Immunochemotherapeutic Strategy– Acute and Chronic ChD
Groups
Control
PBS

DDD 5

DDD 1

Cure
Assessment(CA)

Benz

Enzymatic
Assessment

Parasitemia
qPCR
Survival
Histopathology

NMT expression
& purification
Protein-Ligand
interaction

DDD 1 or DDD5

Day 0

20

25

30

35

40

50

70

100

qPCR
Survival
Histopathology

Figure 9. NMT inhibitors as immunochemotherapeutic treatment for acute and chronic
ChD. A total of 80 Balb/c mice will be used for this experiment. 40 mice will be
inoculated with 1 x 104 CL Brener-LUC T. cruzi trypomastigotes for the early acute
experiment. The late acute experiment will consist of 40 mice inoculated with 1 x 103 CL
Brener-LUC T. cruzi trypomastigotes. In the acute experiment, treatment will be
administered with DDD1 (20 m/kg) for 12 days and DDD5 for (50 mg/kg) 5 days orally,
on the day parasitemia peak is observed. In the late acute experiment, the same dose
will be administered after peak of parasitemia, which is an estimate of 20 dpi. To assess
parasite

load

after

treatment

parasitemia

via

bioluminescence,

qPCR,

and

histopathology. Survival of mice will also be recorded. Enzymatic activity will be
evaluated through UV spectrophotometry and LC-MS.

28

Chapter 3: Assessment of drug and peptide-based vaccine
combination for improved efficacy in the murine model of chronic T.
cruzi infection
3.1

Mucin Associated Surface Protein

T. cruzi is coated with glycosylphosphatidylinositol (GPI) anchored molecules
that are encoded by multigene families of mucins, mucin-associated surface proteins
(MASPs), and trans-sialidases (TS) [33]. Mucins are a dominantly expressed multigene
family in T. cruzi, comprising over 1,377 genes found in TS and mucin genes [34-36].
This parasite utilizes several surface molecules to evade the host immune response
and increase its infiltration into host tissues [37].
A repertoire of MASPs motifs were analyzed using proteomics elucidating that
MASPs are highly abundant in bloodstream trypomastigotes with low expression levels
in amastigote and epimastigote forms of T. cruzi [36]. These motifs are strongly
characterized by N- and C-terminal conserved domains containing a signal peptide for
the GPI-anchor [36]. Previous studies have revealed MASPs contain variable central
region sequences that include repetitive motifs [36]. In culture medium, parasites are
able to secrete vesicles containing different glycoproteins, such as MASPs [34-36].
Since MASPs expression is up regulated in T. cruzi and extracellular vesicles containing
MASPs are released into the environment, these molecules are an attractive target for
the development of a protective vaccine for ChD.

29

3.2

Prophylactic peptide vaccine

As previously mentioned, MASPs contains signal peptides at the N- and Cterminus, which are responsible for signaling the GPI-anchor. Mature vesicles
containing MASPs ~39.7 kDa protein were used to predict B cell, MHC class I and MHC
class II binding sites using immunoinformatics and proteomic analysis. This study
revealed the MASP peptide sequence DAENPGGEVFNDNKKGLSRV, now MASPpep,
which was then synthesized and conjugated to a carrier protein, keyhole limpet
hemocyanin (KLH). MASPpep-KLH was evaluated as a prophylactic vaccine against T.
cruzi where mice were challenged with T. cruzi Y strain trypomastigotes after a series of
immunizations, resulting in an 86% survival (Figure 10A). Noticeably, there was a
significant reduction of parasitic burden in heart, liver, and spleen compared to
nonimmunized control groups (Figure 10B).
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A

B

Figure 10. Survival (A) and parasite load in tissues (B) of infected mice after a series of
immunizations.
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3.3 Hypothesis
Mucin-Associated Surface Protein (MASP) is a highly expressed in T. cruzi and
has been previously validated to prevent the infection of T. cruzi. This prophylactic
peptide vaccine elicited a strong humoral and cell-mediated response, reducing parasite
burden by 97% in challenged mice. For this reason, we hypothesize that the
immunochemotherapeutic approach by combination of MASPpep-KLH vaccine
and Benznidazole can significantly reduce parasitic infection by improving
efficacy and regulating immunological imbalance in the murine model of chronic
Chagas disease.

3.4 Specific aims

Aim 1: To validate MASPpep-KLH as a therapeutic vaccine in combination with
Benznidazole.

Aim 2: To evaluate the humoral and cell mediated immune response in challenged
mice treated with MASPpep-KLH and/or Benznidazole.
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3.5

Materials and methods

3.5.1 Peptide and Compounds
Benznidazole, nitroimidazole derivative was obtained from Roche distributors containing
100 mg of active ingredient per tablet (Rochagon, Roche 7-1051). Mucin-associated
surface protein (DAENPGGEVFNDNKKGLSRV) conjugated to KLH, was synthesized
by Think peptides.

3.5.2 T. cruzi culture
T. cruzi CL-Brener-expressing Luciferase (LUC) were cultured by passage through
BALB/c mice and monkey kidney epithelial cells (LLC-MK2). After 5 passages, BALB/c
mice were infected with 103 trypomastigotes. Bloodstream trypomastigotes were
collected 4 days post-infection and used to infect LLC-MK2 cells. Infected cells were
incubated for 6 to 12 days at 37˚C supplemented with 5% CO2 in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% heat inactivated fetal bovine serum (iFBS)
and 1% penicillin-streptomycin. Tissue culture cell derived trypomastigotes of T. cruzi
CL-Brener-LUC were collected 9 -12 days after infection of LLC-MK2.

3.5.3 Mice strains
Female C3H/HeJ mice (5-8 weeks old) were purchased from The Jackson Laboratory.
The in vivo T. cruzi experiments were performed minimizing the distress and pain for
the animals following the NIH guidance and animal protocol (A-2125) approved by
UTEP’s Institutional Animal Care and Use Committee (IACUC).
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3.5.4 In vivo experiments for chronic phase of ChD

C3H/HeJ (Jackson Laboratory, Bar Harbor, ME) female mice (5-8 weeks old) were
separated into 3 groups of 4 mice. The immunizations were administered via
intraperitoneal (i.p) and BZ treatment was given via oral gavage. The control group was
treated with 100 µl of phosphate buffer saline (PBS, vaccine/drug diluent) once a day.
The second group was immunized with 20 µg/dose/mouse of MASPpep-KLH. The third
group was treated with 25 mg/kg of BZ once a day and 20 µg/dose/mouse of MASPpepKLH, combined. T. cruzi blood stream trypomastigotes were obtained as described
previously. Suspension of 103 parasites per milliliter of DMEM were inoculated via
intraperitoneal (i.p.) injection to designated mice. Treatment was administered 46 dpi via
oral gavage, once a day for 5 days. A total of 4 immunizations were administered
intraperitoneal every 7 days.

3.5.5 Parasite quantification in the chronic phase of ChD via bioluminescence
imaging
C3H/HeJ female mice were injected i.p. with 150 mg/kg of potassium salt D-luciferin
(GoldBio Biotechnology, St. Louis, MO), followed by 2.5 % isoflurane exposure. Ten
minutes after D-luciferin administration, mice were placed and images were acquired at
the IVIS Lumina III In Vivo Imaging System (PerkinElmer, Waltham, MA). Auto exposure
times varied between 1 and 90 seconds depending on signal intensity [27]. After
imaging, mice were recovered and placed in cages below a heating pad. To assess the
parasite burden, regions of interest (ROIs) were drawn using Livingimage v.4.3 software
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to quantify bioluminescence expressed as total flux (photons/second (p/s)) as previously
described [27].

3.5.6 Humoral immune response assessment
Before administering the first immunization, blood was collected by submandibular
venipuncture from each group (PBS, MASPpep-KLH, and MASPpep-KLH+BZ). Blood
was also collected from a naïve group. The blood collections were then centrifuged at
2700 rpm for 10 minutes, to obtain serum. Blood was collected three days after each
immunization and before euthanizing. The antibody titers were analyzed performing an
chemiluminescence enzyme-linked immunosorbent assay (CL-ELISA) against 125
ng/well of MASPpep-KLH. Each sample was done in triplicates and read with a
Luminoskan luminometer microplate reader.

3.5.7 Immunoglobulin Isotyping
MASPpep-specific antibodies were also evaluated via CL-ELISA. IgG1, IgG2a, IgG2b,
IgG3, IgA, IgM, and IgE subtypes were analyzed. 96-well Nunc polystyrene microplates
(Thermo Fisher Scientific) were coated overnight at 4°C with 125 ng/well of MASPpepKLH in 0.2 M carbonate-bicarbonate buffer (CBB). All mouse serum was diluted at
1:100 in 1% BSA in PBS with 0.05% Tween 20. Secondary antibodies conjugated to
HRP were used (goat anti-mouse IgG1-HRP, goat anti-mouse IgG2a-HRP, goat antimouse IgG2b-HRP, and goat anti-mouse IgG3-HRP, goat anti-mouse IgA-HRP, goat
anti-mouse IgM-HRP rat anti-mouse IgE-HRP; Abcam). The antibodies were diluted at
1:2000 in 1% BSA in PBS with 0.05% Tween 20 and 50 μL was added to each well.

35

Plates were incubated for 1 h at 37°C. The reaction was developed with 50 μL SuperSignal Chemiluminescent Substrate (Thermo Fisher Scientific) at 1:8 dilution in CBB
and read using a Luminoskan luminometer microplate reader. Biological replicates were
run for each test group [38].

3.5.8 Evaluation of cytokine production
Th1, Th2, and Th17 cytokines (IL-12p70, IL-2, IFN-g, TNF-a, IL-5, IL-4, IL-10, IL-6 and
Il-17) were evaluated using multiplex kit, MILLIPLEX Mouse Cytokines Magnetic Bead
Panel (EMD Milipore, Billerica, MA). Serum from all immunized groups and naïve group
were analyzed at end point (100 dpi), following manufacturer’s protocol. [38]

3.5.9 DNA extraction
Mice were euthanized at experimental endpoint of 100 dpi by CO2 overdose and
infected tissues were harvested (heart, liver, spleen, lungs, stomach, cecum, intestine,
and skeletal muscle). All samples were spiked with 5 µL of a 40 pg/µL of linearized
pUC57 plasmid containing a sequence from Arabidopsis thaliana as an internal
amplification control (IAC) as previously described[39]. Genomic DNA was extracted
from 30 mg of infected tissues utilizing High Pure PCR Template Preparation Kit and
manufacture protocol was followed (Roche Molecular Systems, Indianapolis, IN).
Additionally, 30 mg of genomic DNA was also extracted from non-infected mice tissues
(negative

control).

Extracted

DNA

was

Spectrophotometer.
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quantified

by

Nanodrop

1000

3.5.10 Quantitative real time PCR (qPCR) to measure parasitic load
100 ng of genomic DNA was measured for parasitic load based on a DNA standard
curve ranging from 0.5 to 105 T. cruzi trypomastigotes/mL. Amplification of satellite DNA
of

T.

cruzi

was

achieved

using

ASTCGGCTGATCGTTTTCGA

-3’),

AATTCCTCCAAGCAGCGGATA

-3’),

750

750
and

nM
nM

50

nM

of
of
of

forward
reverse
TaqMan

primer
primer
probe

(5’(5’(FAM-

CACACACTGGACACCAA-NFQ-MGB). The internal amplification control (IAC) was
amplified using 100 nM of forward primer (5’- ACCGTCATGGAACAGCACGTA -3’), 100
nM of reverse primer (5’- CTCCCGCAACAAACCCTATAAAT -3’), and 50 nM of
TaqMan probe (VIC-AGCATCTGTTCTTGAAGGT-NFQ-MGB). Triplicates of each
sample were processed in Step One Plus Real Time PCR System (Applied
Biosystems). qPCR conditions consisted of 50˚C for 2 min, 94˚C for 10 min, followed by
40 cycles at 95˚C for 15 sec and 58˚C for 1 min.
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3.6

Results

3.6.1 Parasite burden in tissues
Parasitic infection was followed for 100 days in C3H/HeJ mice infected i.p with
103 CL Brener-LUC. T. cruzi infection was observed by in vivo bioluminescent imaging.
In this chronic model, the reduction of parasitic infection was observed after 44 dpi.
Treatment was administered at 46 dpi. MASPpep-KLH was administered i.p at
20µg/dose/mouse and

a combinational treatment of

50 mg/kg of

BZ and

20µg/dose/mouse. BZ was administered via oral gavage for five consecutive days. As
observed in Figure 11., the parasite load showed no significant decrease in parasitic
infection compared to challenged mice only.
Quantitative real time PCR was performed to validate that combinational therapy
is able to reduce infection and display parasite clearance in immunized mice. All organs
were collected at experimental endpoint, however, only tissues that had a significant
decrease in parasitic burden are shown (heart, liver, spleen, intestine, colon, and
skeletal muscle). MASPpep-KLH alone had a decrease in parasite burden in the heart,
a hallmark for ChD. Additionally, there were lower parasite loads in spleen, intestine,
and skeletal muscle in MASPpep-KLH compared to placebo and MASPpep-KLH/BZ
groups (Figure 12).
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A

B
(I)

(II)

(III
)

Figure 11. Ventral bioluminescence quantification of T. cruzi with immunochemotherapy
and weight observation after initial treatment. (A) Treatment started at 46 dpi for a total
of 5 days by oral gavage. No significant decrease in parasitic infection was
demonstrated using bioluminescence in MASPpep-KLH alone (red), MASPpep-KLH
with BZ (green), and Placebo challenged mice (blue). (B) Ventral view images of the
C3H/HeJ mouse were acquired in chronological order from day 46 to 100 dpi. The log10
scale shows bioluminescent intensity from a minimum of 1.84x104 (blue) to high
39

2.36x106 (red).

(I) Challenged, PBS vehicle control. (II) Infected, immunized with

MASPpep-KLH alone at 20 µg/dose/mouse (III) Infected, treated with BZ at 50 mg/kg
from day 46 to 50 dpi and 20µg/dose/mouse of MASPpep-KLH.
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Figure 12. Manifestation of 1x103 CL Brener-LUC trypomastigotes in C3H/HeJ tissues.
Mice immunized with MASPpep-KLH and/or BZ showed a decrease in parasite burden
in the intestine, colon, liver, and spleen. Also, MASPpep-KLH alone had a lower
parasite burden in the heart compared to challenged mice and BZ treated mice, which is
one of the hallmarks of ChD.
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3.6.2 MASPpep-KLH elicits a humoral immune response
Mice immunized with MASPpep-KLH and MASPpep-KLH+BZ demonstrated to have an
antigen-specific antibody response (Figure 13). There was a significant production of
antibodies in MASPpep-KLH+BZ after the second boost and remains consistent until
the endpoint. Assessment of humoral isotyping is essential to determine the type of
antibodies that are produced and which have antiparasitic properties. Both MASPpepKLH and/or BZ did increase antigen specific IgG1 levels compared to challenge only
mice. In the experiment IgM, IgG2a and IgG2b levels were higher compared to IgG1
(Figure 14. A-C, E). Studies have shown that the induced subtypes are considered to
have high anti-parasitic properties [40]. Positively, IgE levels are significantly lower
indicating no response to allergen (Figure 14, G).
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Figure 13. Evaluation of antibody production in response to MASPpep-KLH immunized
mice. CL-ELISA against MASPpep-KLH using serum obtained before prime (BP, Day
46), prime (P, Day 49), boost 1–3 (B1-B3), and at endpoint (100 dpi) from challenged
mice, and immunized mice with MASPpep-KLH and MASPpep-KLH+BZ. High levels of
antibodies were detected in immunized mice, MASPpep-KLH+BZ especially.
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Figure 14. MASPpep-KLH induces immunoglobulin (Ig) subtypes production. (A-G)
Antibody isotyping (IgG1, IgG2a, IgG2b, IgG3, IgA, IgM and IgE) of immunized mice
serum obtained from each time point. (BP, P, B1-3, and EP). MASPpep-KLH antigenspecific antibody production levels were much higher in IgG1, IgG2a, IgG2b and IgM (AC, E) compared to challenge only mice immunized with PBS only.
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3.6.3 Serum cytokine profiling
A Th1, Th2, and Th17 cytokine panel was evaluated for analysis of MASPpep-KLH
and/or BZ therapy in sera of immunized mice at endpoint (100 dpi) consisted of IL-1α,
IL-2, IL-4, IL3, IL-5, IL-6, IL-7, IL-10, IL-12 (p70), IL-15, IL-17, IFN-γ, TNF-α. MASPpepKLH alone had a higher amount of IL-12 (p70), IFN-γ, IL-3, IL-4, IL-5, and IL-6 cytokine
production compared to challenge only mice (Figure 15). Contrarily, combinational
treatment of MASPpep-KLH and BZ had a reduction in all cytokines exhibited. Mice that
received MASPpep-KLH treatment had an increased secretion of IL-12(p70), IL-3, IL-6,
IL-5 and IFN-γ. IL-12(p70). There were higher levels of IL-10 compared to IL-4 in
MASPpep-KLH and MASPpep-KLH+BZ (Figure 15 E,F). Significant amounts of IL12(p70) were secreted in MASPpep-KLH only immunized group (Figure 15A).
Moreover, the cytokine response included increases in both Th1 (IFN-γ, IL-12 (p70)),
Th2 (IL-4, IL-10, IL-5) cytokines, anti-inflammatory molecules (IL-10) and Treg cells in
MASPpep-KLH only treated mice. MASPpep-KLH and BZ immunized mice had a down
regulation of Th1 (IL-12 (p70), IL-3, IL-15), Th2 (IL-10), Th17 (IL-17), and IL-7 Treg
cytokines.
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Figure 15. Cytokine profile of MASPpep-KLH and MASPpep-KLH+BZ immunizations.
(A-D,G,I-K) Th1 cytokines IL-12p70, IL-2, IFN-γ, TNF-α,IL-3, IL-6, IL-1α. (E,F,H) Th2
cytokines IL-4 and IL-10. (M,N) Th17 and Treg cytokines IL-17, IL-7.
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3.7

Discussion
ChD is an endemic infection that is becoming a global concern, affecting an

estimate of 10 million people in Latin American and is increasing due to nonspecific
symptoms [10, 28]. Although approved by the FDA, BZ is highly toxic and has low
efficacy in the chronic phase. In addition, it has not been proven to reverse the
development of cardiomyopathy [41]. The chronic mouse model of T. cruzi has a
disadvantage when investigating the development of the disease, due to intracellular
amastigotes residing in smooth tissue remaining dormant, in contrast to the acute phase
where circulating trypomastigotes can be readily detected [27]. T. cruzi primarily resides
in the gastrointestinal tract during the chronic infection, where mice have also shown to
develop

chronic

myocarditis

and

cardiac

fibrosis

[27].

Immunochemotherapy

approaches have been explored by several research groups by combining antiparasitic
drugs and an immunostimulatory molecule such as a recombinant DNA or protein.
Recently, the highly expressed mucin-associated surface protein (MASP) on the
surface of T. cruzi has been validated as a protective vaccine against T. cruzi. Here, this
20-mer synthetic MASP peptide (MASPpep-KLH) elicited a humoral and cell-mediated
immune response, which made it a potential candidate as a therapeutic vaccine against
T. cruzi. A high antibody response was observed by MASPpep-KLH alone and
MASPpep-KLH+BZ, when compared to PBS, challenged group (Figure 13). In this study
there were evident levels of IgG1 and IgM isotypes in MASPpep-KLH and/or BZ,
similarly, these isotypes were observed in the protective vaccine previously described.
Interestingly, IgG1 has been described to reduce mortality and aid in clearing parasitic
infections [40].
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High levels of IL-12p70, IL-10, IL-1α, IL-15 were observed in MASPpep-KLH
alone immunized mice, which are related to controlling T. cruzi infection. Cytokine levels
are significantly lower in MASPpep-KLH with BZ in comparison to MASPpep-KLH alone
and challenged group. IL-4 was shown to be higher in MASPpep-KLH alone, which is
an isotype switch-stimulating factor for B cells. A Th1 response has been known to be
required in controling T. cruzi infection by producing IFN-γ [42]. Moreover, Th1 cells are
responsible for macrophage activation by eliminating antigens through the production of
IFN-γ [11] and producing nitric oxide (iNOS), an important immune system frontline for
eliminating intracellular pathogens [43]. Furthermore, the combination treatment
decreased IL-12, IFN-γ, IL-4, IL-10, as well as a decrease in IL-3, IL-15, and IL-17.
Activation of IFN-γ producing CD4+ and CD8+ memory T cells is often correlated to Th1
and Th2 equilibrium. This response results in parasitic resistance, however, parasitemia
may increase if IFN-γ is absent [44]. MASPpep-KLH immunized and challenged mice
displayed in increase of Th17 response, specifically IL-17, which are neutralizing
antibodies that promote immunity to infected macrophages, by providing mediators to
CD8+ T cells [43]. MASPpep-KLH immunized group elicited a strong production IL-12
inducing a Th1 response, which promotes resistance to T. cruzi. IL-12 is a
heterodimeric pro-inflammatory cytokine that activates NK cells and induces
differentiation CD4+ T cells to Th1 effector cells enhancing cytotoxicity [45-47]. IL-10 is
an Th2 anti-inflammatory cytokine that is secreted to maintain a homeostasis [45]. The
relationship between IL-10 and IL-12p70 is evident in MASPpep-KLH immunized mice
treated with BZ, indication of a potential stability of anti- and pro-inflammatory cytokines.
T. cruzi-specific IFN-γ CD4+ T cells produce IL-2 and IL-15, which correlates with
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cytokine trend found in MASPpep-KLH immunized group. Deficiency of IL-12 and IFN-γ
results in mortality, and also increased levels of IFN-γ and IL-10 results in
cardiomyopathy [48]. BZ treatment decreases the parasite load, thus diminishing the
antigen that is required to maintain the T. cruzi-specific effector T cells. BZ treatment
enhanced phagocytosis, parasite destruction and cytokine release by macrophages
[49].
Furthermore, parasitic load was measured by absolute quantification using qPCR
exhibiting 71% and 94.2% reduction in MASPpep-KLH and/or BZ groups in the
intestines, which is one of the major manifestations of T. cruzi. There was approximately
a 30% decrease in spleen MASPpep-KLH and/or BZ, and also a 32% reduction heart
parasitic burden in MASPpep-KLH alone immunized mice.
All together, we observed that MASPpep-KLH and/or BZ immunized mice elicited
high levels of IgG antibodies, together with a T-cell mediated immune response. A proinfllamatory and regulatory serum cytokine equilibrium (IL-4, IL-10, IL-12, IL-17, and
IFN-γ) was observed, which may contribute to parasitic clearance and lower mortality,
by controlling parasitic infection and inflammation. Inopportunely, BZ does not reverse
cardiomyopathy, which is the main cause of death in chronic individuals. In this regard,
it is important to elicit a strong immune response stimulated by MASPpep-KLH and
suboptimal dosage of BZ to help reduce parasitic burden and enhance tissue repair
mediators. While this immunotherapy approach did not completely clear infection, it
resulted in reduced parasitic burden in intestinal and cardiac tissues with MASPpepKLH and/or BZ treatment.

49

3.8

Acknowledgments

Authors thank the NIH for support through Grant No. 5SC1GM089558 to R.A. S-D.
Thanks to the Biomolecule Analysis, the Genomic Analysis and the Cytometry,
Screening and Imaging Core Facilities at the University of Texas at El Paso supported
by NIMHD-NIH Grant No. 5G12MD007592. Thanks to the Border Biomedical Research
Center pilot grant to R.A.M, supported by RCMI program Grant No. 2G12MD007592,
from the NIMHD-NIH. The RISE Scholars Program at UTEP through NIGMS Grant No
R25GM069621-09 supported E.I.

50

References
1.

Wilkinson SR, Kelly JM. Trypanocidal drugs: mechanisms, resistance and new

targets. Expert Rev Mol Med. 2009;11:e31. doi: 10.1017/S1462399409001252. PubMed
PMID: 19863838.
2.

Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies

and advances. Trends Parasitol. 2003;19(11):495-501. PubMed PMID: 14580960.
3.

Perin L, Moreira da Silva R, Fonseca KD, Cardoso JM, Mathias FA, Reis LE, et

al. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration
in

Mice.

Antimicrob

10.1128/AAC.02410-16.

Agents

Chemother.

PubMed

PMID:

2017;61(4).
28167558;

Epub

PubMed

2017/02/09.

doi:

Central

PMCID:

disease.

Lancet.

PMCPMC5365712.
4.

Rassi

A,

Jr.,

Rassi

A,

Marin-Neto

JA.

Chagas

2010;375(9723):1388-402. doi: 10.1016/S0140-6736(10)60061-X. PubMed PMID:
20399979.
5.

Roberts AJ, Fairlamb AH. The N-myristoylome of Trypanosoma cruzi. Sci Rep.

2016;6:31078. doi: 10.1038/srep31078. PubMed PMID: 27492267; PubMed Central
PMCID: PMCPMC4974623.
6.

Tanowitz HB, Kirchhoff LV, Simon D, Morris SA, Weiss LM, Wittner M. Chagas'

disease. Clin Microbiol Rev. 1992;5(4):400-19. PubMed PMID: 1423218; PubMed
Central PMCID: PMCPMC358257.
7.

Bonney KM. Chagas disease in the 21st century: a public health success or an

emerging threat? Parasite. 2014;21:11. doi: 10.1051/parasite/2014012. PubMed PMID:
24626257; PubMed Central PMCID: PMCPMC3952655.
51

8.

Buckner FS, Urbina JA. Recent Developments in Sterol 14-demethylase

Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist. 2012;2:236-42. doi:
10.1016/j.ijpddr.2011.12.002. PubMed PMID: 23277882; PubMed Central PMCID:
PMCPMC3531554.
9.

Teixeira DE, Benchimol M, Crepaldi PH, de Souza W. Interactive multimedia to

teach the life cycle of Trypanosoma cruzi, the causative agent of Chagas disease. PLoS
Negl Trop Dis. 2012;6(8):e1749. doi: 10.1371/journal.pntd.0001749. PubMed PMID:
22970330; PubMed Central PMCID: PMCPMC3429381.
10.

Gatto M, Oliveira LRC, De Nuzzi Dias F, Araujo Junior JP, Lima CRG, Lordelo

EP, et al. Benznidazole affects expression of Th1, Th17 and Treg cytokines during
acute experimental Trypanosoma cruzi infection. J Venom Anim Toxins Incl Trop Dis.
2017;23:47. Epub 2017/12/20. doi: 10.1186/s40409-017-0137-4. PubMed PMID:
29255475; PubMed Central PMCID: PMCPMC5727918.
11.

Jones K, Versteeg L, Damania A, Keegan B, Kendricks A, Pollet J, et al.

Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas
Disease. Infect Immun. 2018;86(4). Epub 2018/01/10. doi: 10.1128/IAI.00876-17.
PubMed PMID: 29311242; PubMed Central PMCID: PMCPMC5865041.
12.

Wright MH, Heal WP, Mann DJ, Tate EW. Protein myristoylation in health and

disease. J Chem Biol. 2010;3(1):19-35. doi: 10.1007/s12154-009-0032-8. PubMed
PMID: 19898886; PubMed Central PMCID: PMCPMC2816741.
13.

Goldston AM, Sharma AI, Paul KS, Engman DM. Acylation in trypanosomatids:

an essential process and potential drug target. Trends Parasitol. 2014;30(7):350-60.

52

doi: 10.1016/j.pt.2014.05.003. PubMed PMID: 24954795; PubMed Central PMCID:
PMCPMC4190163.
14.

Gelb MH, Van Voorhis WC, Buckner FS, Yokoyama K, Eastman R, Carpenter

EP, et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry
targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol
Biochem Parasitol. 2003;126(2):155-63. PubMed PMID: 12615314.
15.

Boutin JA. Myristoylation. Cell Signal. 1997;9(1):15-35. PubMed PMID: 9067626.

16.

Frearson JA, Brand S, McElroy SP, Cleghorn LA, Smid O, Stojanovski L, et al. N-

myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature.
2010;464(7289):728-32. doi: 10.1038/nature08893. PubMed PMID: 20360736; PubMed
Central PMCID: PMCPMC2917743.
17.

Resh

MD.

Targeting

protein

lipidation

in

disease.

Trends

Mol

Med.

2012;18(4):206-14. doi: 10.1016/j.molmed.2012.01.007. PubMed PMID: 22342806;
PubMed Central PMCID: PMCPMC3322242.
18.

Wright MH, Paape D, Storck EM, Serwa RA, Smith DF, Tate EW. Global analysis

of protein N-myristoylation and exploration of N-myristoyltransferase as a drug target in
the neglected human pathogen Leishmania donovani. Chem Biol. 2015;22(3):342-54.
doi: 10.1016/j.chembiol.2015.01.003. PubMed PMID: 25728269; PubMed Central
PMCID: PMCPMC4372256.
19.

Price HP, Menon MR, Panethymitaki C, Goulding D, McKean PG, Smith DF.

Myristoyl-CoA:protein N-myristoyltransferase, an essential enzyme and potential drug
target

in

kinetoplastid

parasites.

J

Biol

Chem.

10.1074/jbc.M211391200. PubMed PMID: 12488459.

53

2003;278(9):7206-14.

doi:

20.

Wright MH, Clough B, Rackham MD, Rangachari K, Brannigan JA, Grainger M,

et al. Validation of N-myristoyltransferase as an antimalarial drug target using an
integrated

chemical

10.1038/nchem.1830.

biology

approach.

PubMed

PMID:

Nat

Chem.

24451586;

2014;6(2):112-21.

PubMed

Central

doi:

PMCID:

PMCPMC4739506.
21.

Herrera LJ, Brand S, Santos A, Nohara LL, Harrison J, Norcross NR, et al.

Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in MammalDwelling Stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2016;10(4):e0004540.
Epub 2016/04/30. doi: 10.1371/journal.pntd.0004540. PubMed PMID: 27128971;
PubMed Central PMCID: PMCPMC4851402.
22.

Chen CA, Manning DR. Regulation of G proteins by covalent modification.

Oncogene.

2001;20(13):1643-52.

doi:

10.1038/sj.onc.1204185.

PubMed

PMID:

11313912.
23.

Emmer BT, Souther C, Toriello KM, Olson CL, Epting CL, Engman DM.

Identification of a palmitoyl acyltransferase required for protein sorting to the flagellar
membrane. J Cell Sci. 2009;122(Pt 6):867-74. doi: 10.1242/jcs.041764. PubMed PMID:
19240115; PubMed Central PMCID: PMCPMC2714429.
24.

Zhao C, Ma S. Recent advances in the discovery of N-myristoyltransferase

inhibitors.

ChemMedChem.

2014;9(11):2425-37.

doi:

10.1002/cmdc.201402174.

PubMed PMID: 25125080.
25.

Brand S, Wyatt P. N-myristoyl transferase inhibitors. Google Patents; 2010.

54

26.

Brener Z. Therapeutic activity and criterion of cure on mice experimentally

infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo. 1962;4:389-96.
PubMed PMID: 14015230.
27.

Lewis MD, Fortes Francisco A, Taylor MC, Burrell-Saward H, McLatchie AP,

Miles MA, et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections
reveals tissue-specific parasite dynamics and heart disease in the absence of locally
persistent infection. Cell Microbiol. 2014;16(9):1285-300. doi: 10.1111/cmi.12297.
PubMed PMID: 24712539; PubMed Central PMCID: PMCPMC4190689.
28.

Debierre-Grockiego F. Glycolipids are potential targets for protozoan parasite

diseases. Trends Parasitol. 2010;26(8):404-11. doi: 10.1016/j.pt.2010.04.006. PubMed
PMID: 20483663.
29.

Field MC, Carrington M. The trypanosome flagellar pocket. Nat Rev Microbiol.

2009;7(11):775-86. doi: 10.1038/nrmicro2221. PubMed PMID: 19806154.
30.

Calvet CM, Vieira DF, Choi JY, Kellar D, Cameron MD, Siqueira-Neto JL, et al. 4-

Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with
improved pharmacokinetic profile and in vivo potency. J Med Chem. 2014;57(16):69897005. doi: 10.1021/jm500448u. PubMed PMID: 25101801; PubMed Central PMCID:
PMCPMC4148169.
31.

Doyle PS, Chen CK, Johnston JB, Hopkins SD, Leung SS, Jacobson MP, et al. A

nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
Antimicrob

Agents

Chemother.

2010;54(6):2480-8.

doi:

10.1128/AAC.00281-10.

PubMed PMID: 20385875; PubMed Central PMCID: PMCPMC2876414.

55

32.

Gunatilleke SS, Calvet CM, Johnston JB, Chen CK, Erenburg G, Gut J, et al.

Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis.
2012;6(7):e1736. doi: 10.1371/journal.pntd.0001736. PubMed PMID: 22860142;
PubMed Central PMCID: PMCPMC3409115.
33.

Nakayasu ES, Sobreira TJ, Torres R, Jr., Ganiko L, Oliveira PS, Marques AF, et

al. Improved proteomic approach for the discovery of potential vaccine targets in
Trypanosoma cruzi. J Proteome Res. 2012;11(1):237-46. Epub 2011/11/26. doi:
10.1021/pr200806s.

PubMed

PMID:

22115061;

PubMed

Central

PMCID:

PMCPMC3253764.
34.

De Pablos LM, Gonzalez GG, Solano Parada J, Seco Hidalgo V, Diaz Lozano

IM, Gomez Samblas MM, et al. Differential expression and characterization of a
member of the mucin-associated surface protein family secreted by Trypanosoma cruzi.
Infect Immun. 2011;79(10):3993-4001. Epub 2011/07/27. doi: 10.1128/IAI.05329-11.
PubMed PMID: 21788387; PubMed Central PMCID: PMCPMC3187265.
35.

Bastos IM, Grellier P, Martins NF, Cadavid-Restrepo G, de Souza-Ault MR,

Augustyns K, et al. Molecular, functional and structural properties of the prolyl
oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry
into mammalian cells. Biochem J. 2005;388(Pt 1):29-38. Epub 2004/12/08. doi:
10.1042/BJ20041049.

PubMed

PMID:

15581422;

PubMed

Central

PMCID:

PMCPMC1186690.
36.

Bartholomeu DC, Cerqueira GC, Leao AC, daRocha WD, Pais FS, Macedo C, et

al. Genomic organization and expression profile of the mucin-associated surface protein
(masp) family of the human pathogen Trypanosoma cruzi. Nucleic Acids Res.

56

2009;37(10):3407-17. Epub 2009/04/02. doi: 10.1093/nar/gkp172. PubMed PMID:
19336417; PubMed Central PMCID: PMCPMC2691823.
37.

Buscaglia CA, Campo VA, Frasch AC, Di Noia JM. Trypanosoma cruzi surface

mucins: host-dependent coat diversity. Nat Rev Microbiol. 2006;4(3):229-36. doi:
10.1038/nrmicro1351. PubMed PMID: 16489349.
38.

Iniguez E, Schocker NS, Subramaniam K, Portillo S, Montoya AL, Al-Salem WS,

et al. An alpha-Gal-containing neoglycoprotein-based vaccine partially protects against
murine cutaneous leishmaniasis caused by Leishmania major. PLoS Negl Trop Dis.
2017;11(10):e0006039. Epub 2017/10/27. doi: 10.1371/journal.pntd.0006039. PubMed
PMID: 29069089; PubMed Central PMCID: PMCPMC5673233.
39.

Duffy T, Bisio M, Altcheh J, Burgos JM, Diez M, Levin MJ, et al. Accurate real-

time PCR strategy for monitoring bloodstream parasitic loads in chagas disease
patients. PLoS Negl Trop Dis. 2009;3(4):e419. doi: 10.1371/journal.pntd.0000419.
PubMed PMID: 19381287; PubMed Central PMCID: PMCPMC2667272.
40.

Serna C, Lara JA, Rodrigues SP, Marques AF, Almeida IC, Maldonado RA. A

synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as
candidate for a vaccine against Chagas disease. Vaccine. 2014;32(28):3525-32. Epub
2014/05/06. doi: 10.1016/j.vaccine.2014.04.026. PubMed PMID: 24793944; PubMed
Central PMCID: PMCPMC4058865.
41.

Francisco AF, Jayawardhana S, Lewis MD, White KL, Shackleford DM, Chen G,

et al. Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more
effectively in the chronic stage than in the acute stage. Sci Rep. 2016;6:35351. Epub

57

2016/10/18. doi: 10.1038/srep35351. PubMed PMID: 27748443; PubMed Central
PMCID: PMCPMC5066210.
42.

Rosas-Jorquera CE, Sardinha LR, Pretel FD, Bombeiro AL, D'Imperio Lima MR,

Alvarez JM. Challenge of chronically infected mice with homologous trypanosoma cruzi
parasites enhances the immune response but does not modify cardiopathy: implications
for the design of a therapeutic vaccine. Clin Vaccine Immunol. 2013;20(2):248-54. Epub
2012/12/21. doi: 10.1128/CVI.00032-12. PubMed PMID: 23254299; PubMed Central
PMCID: PMCPMC3571278.
43.

Cai CW, Blase JR, Zhang X, Eickhoff CS, Hoft DF. Th17 Cells Are More

Protective Than Th1 Cells Against the Intracellular Parasite Trypanosoma cruzi. PLoS
Pathog. 2016;12(10):e1005902. Epub 2016/10/04. doi: 10.1371/journal.ppat.1005902.
PubMed PMID: 27695083; PubMed Central PMCID: PMCPMC5047564.
44.

Limon-Flores AY, Cervera-Cetina R, Tzec-Arjona JL, Ek-Macias L, Sanchez-

Burgos G, Ramirez-Sierra MJ, et al. Effect of a combination DNA vaccine for the
prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+
T

cells.

Vaccine.

2010;28(46):7414-9.

Epub

2010/09/21.

doi:

10.1016/j.vaccine.2010.08.104. PubMed PMID: 20850536.
45.

Ma X, Yan W, Zheng H, Du Q, Zhang L, Ban Y, et al. Regulation of IL-10 and IL-

12 production and function in macrophages and dendritic cells. F1000Res. 2015;4.
Epub 2016/02/27. doi: 10.12688/f1000research.7010.1. PubMed PMID: 26918147;
PubMed Central PMCID: PMCPMC4754024.
46.

Yu CR, Lin JX, Fink DW, Akira S, Bloom ET, Yamauchi A. Differential utilization

of Janus kinase-signal transducer activator of transcription signaling pathways in the

58

stimulation of human natural killer cells by IL-2, IL-12, and IFN-alpha. J Immunol.
1996;157(1):126-37. Epub 1996/07/01. PubMed PMID: 8683106.
47.

Aliberti JC, Cardoso MA, Martins GA, Gazzinelli RT, Vieira LQ, Silva JS.

Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by
murine

macrophages

in

response

to

live

trypomastigotes.

Infect

Immun.

1996;64(6):1961-7. Epub 1996/06/01. PubMed PMID: 8675294; PubMed Central
PMCID: PMCPMC174023.
48.

Longhi SA, Atienza A, Perez Prados G, Buying A, Balouz V, Buscaglia CA, et al.

Cytokine production but lack of proliferation in peripheral blood mononuclear cells from
chronic Chagas' disease cardiomyopathy patients in response to T. cruzi ribosomal P
proteins. PLoS Negl Trop Dis. 2014;8(6):e2906. doi: 10.1371/journal.pntd.0002906.
PubMed PMID: 24901991; PubMed Central PMCID: PMCPMC4046937.
49.

Albareda MC, Laucella SA. Modulation of Trypanosoma cruzi-specific T-cell

responses after chemotherapy for chronic Chagas disease. Mem Inst Oswaldo Cruz.
2015;110(3):414-21. Epub 2015/05/21. doi: 10.1590/0074-02760140386. PubMed
PMID: 25993507; PubMed Central PMCID: PMCPMC4489479.

59

Appendix
List of publications and manuscripts
1. E. Iniguez, N. S. Schocker, K. Subramaniam, S. Portillo, A. L. Montoya, W. S. AlSalem, C. L. Torres, F. Rodriguez, O. C. Moreira, A. Acosta-Serrano, K. Michael, I. C.
Almeida, and R. A. Maldonado. An α-Gal-containing neoglycoprotein-based vaccine
partially protects against murine cutaneous leishmaniasis caused by Leishmania major.
PLOS Neglected Tropical Diseases. doi: 10.1371/journal.pntd.0006039

2. E. Iniguez, A. Varela-Ramirez, A. Martínez, C. L. Torres, R. A. Sánchez-Delgado,
and R. A. Maldonado. (2016) Ruthenium-Clotrimazole complex has significant efficacy
in the murine model of cutaneous leishmaniasis. Acta Tropica. 164:402-410. doi:
10.1016/j.actatropica.2016.09.029.

3. Two more manuscripts in preparation.

60

Vita
Caresse Lynn Torres was born on July 10, 1990 in El Paso Texas, the oldest of
six children. She acquired her Bachelor of Science degree in Biology in Fall 2013 from
the University of Texas at El Paso (UTEP). In August 2015, she was accepted to the
Master of Science program at UTEP under the mentorship of Dr. Rosa A. Maldonado at
the laboratory of molecular and anti-parasitic therapies. For the last five years, her
research has focused on the development of novel chemotherapies and potential
vaccine candidates against the neglected disease – Chagas Disease.
Moreover, she has two co-author manuscripts and two more in preparation, and
presented her research at local and national meetings. After graduation, she hopes to
continue working with infectious disease and contribute her knowledge of science to
third world countries by joining the Peace Corps.

Permanent Address: 7333 Desierto Luna
El Paso, Texas 79912
United States

This dissertation was typed by Caresse Lynn Torres

61

